CETP
Basic information
Region (hg38): 16:56961923-56983845
Links
Phenotypes
GenCC
Source:
- cholesterol-ester transfer protein deficiency (Strong), mode of inheritance: AD
- cholesterol-ester transfer protein deficiency (Supportive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hyperalphalipoproteinemia 1 | AD/AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Cardiovascular | 6738363; 3937535; 3867663; 2215607; 8675707; 12080388; 12499392; 15840744; 16049032; 17952847; 18354102; 19060911; 19428034; 20686565; 21354572; 21488146; 22122993; 22339301 |
ClinVar
This is a list of variants' phenotypes submitted to
- Hyperalphalipoproteinemia 1 (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CETP gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 30 | 40 | ||||
missense | 83 | 14 | 102 | |||
nonsense | 5 | |||||
start loss | 0 | |||||
frameshift | 7 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 9 | 2 | 2 | 13 | ||
non coding | 33 | 43 | 77 | |||
Total | 2 | 5 | 93 | 77 | 57 |
Highest pathogenic variant AF is 0.0000657
Variants in CETP
This is a list of pathogenic ClinVar variants found in the CETP region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-56961996-T-A | Likely benign (Jan 05, 2024) | |||
16-56962002-C-T | Hyperalphalipoproteinemia 1 | Uncertain significance (-) | ||
16-56962022-G-T | not specified | Uncertain significance (Jun 30, 2022) | ||
16-56962023-C-G | Hyperalphalipoproteinemia 1 | Benign (Jan 24, 2024) | ||
16-56962023-C-T | not specified | Likely benign (Jun 30, 2022) | ||
16-56962045-C-A | Hyperalphalipoproteinemia 1 • CETP-related disorder | Benign/Likely benign (Jan 29, 2024) | ||
16-56962047-C-T | Uncertain significance (Jan 16, 2024) | |||
16-56962052-G-A | not specified | Conflicting classifications of pathogenicity (Jun 06, 2023) | ||
16-56962063-C-T | Hyperalphalipoproteinemia 1 | Benign (Jan 12, 2018) | ||
16-56962064-G-A | Uncertain significance (May 25, 2023) | |||
16-56962068-G-A | Conflicting classifications of pathogenicity (Nov 01, 2023) | |||
16-56962070-C-T | Uncertain significance (Oct 05, 2021) | |||
16-56962071-G-A | Hyperalphalipoproteinemia 1 | Uncertain significance (Aug 08, 2023) | ||
16-56962087-C-T | Likely benign (Aug 14, 2023) | |||
16-56962148-C-A | Likely benign (Mar 14, 2020) | |||
16-56962192-C-A | Benign (Sep 17, 2018) | |||
16-56962246-T-C | Benign (Aug 30, 2018) | |||
16-56962299-G-A | Benign (Aug 30, 2018) | |||
16-56962367-C-T | Likely benign (Nov 07, 2018) | |||
16-56962376-G-A | Coronary artery disorder | Benign (May 12, 2022) | ||
16-56962733-GCC-G | Benign (Aug 30, 2018) | |||
16-56962737-C-A | Benign (Aug 30, 2018) | |||
16-56962795-G-T | Likely benign (Apr 01, 2019) | |||
16-56963017-C-G | Uncertain significance (May 17, 2023) | |||
16-56963051-C-T | Hyperalphalipoproteinemia 1 | Likely pathogenic (Aug 25, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CETP | protein_coding | protein_coding | ENST00000200676 | 16 | 21996 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.19e-23 | 0.000152 | 125640 | 1 | 107 | 125748 | 0.000430 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.526 | 290 | 266 | 1.09 | 0.0000153 | 3240 |
Missense in Polyphen | 56 | 62.346 | 0.89821 | 827 | ||
Synonymous | -0.735 | 125 | 115 | 1.09 | 0.00000768 | 962 |
Loss of Function | -0.612 | 33 | 29.4 | 1.12 | 0.00000166 | 315 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00105 | 0.00105 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000489 | 0.000489 |
Finnish | 0.00144 | 0.00143 |
European (Non-Finnish) | 0.000238 | 0.000237 |
Middle Eastern | 0.000489 | 0.000489 |
South Asian | 0.000490 | 0.000457 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the transfer of neutral lipids, including cholesteryl ester and triglyceride, among lipoprotein particles. Allows the net movement of cholesteryl ester from high density lipoproteins/HDL to triglyceride-rich very low density lipoproteins/VLDL, and the equimolar transport of triglyceride from VLDL to HDL (PubMed:3600759, PubMed:24293641). Regulates the reverse cholesterol transport, by which excess cholesterol is removed from peripheral tissues and returned to the liver for elimination (PubMed:17237796). {ECO:0000269|PubMed:24293641, ECO:0000303|PubMed:17237796, ECO:0000305|PubMed:3600759}.;
- Disease
- DISEASE: Hyperalphalipoproteinemia 1 (HALP1) [MIM:143470]: A condition characterized by high levels of high density lipoprotein (HDL) and increased HDL cholesterol levels. {ECO:0000269|PubMed:12091484, ECO:0000269|PubMed:2215607, ECO:0000269|PubMed:8408659}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Cholesterol metabolism - Homo sapiens (human);Composition of Lipid Particles;Statin Pathway;LDL remodeling;HDL remodeling;Transport of small molecules;Plasma lipoprotein assembly, remodeling, and clearance;Plasma lipoprotein remodeling
(Consensus)
Recessive Scores
- pRec
- 0.370
Intolerance Scores
- loftool
- 0.970
- rvis_EVS
- -0.06
- rvis_percentile_EVS
- 48.84
Haploinsufficiency Scores
- pHI
- 0.161
- hipred
- N
- hipred_score
- 0.123
- ghis
- 0.396
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.681
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- triglyceride metabolic process;lipid transport;cholesterol metabolic process;negative regulation of macrophage derived foam cell differentiation;regulation of cholesterol efflux;phospholipid transport;cholesterol transport;triglyceride transport;very-low-density lipoprotein particle remodeling;low-density lipoprotein particle remodeling;high-density lipoprotein particle remodeling;cholesterol homeostasis;reverse cholesterol transport;phosphatidylcholine metabolic process;lipid homeostasis;phospholipid homeostasis;triglyceride homeostasis
- Cellular component
- extracellular region;extracellular space;vesicle;high-density lipoprotein particle;extracellular exosome
- Molecular function
- lipid transporter activity;phospholipid transporter activity;lipid binding;cholesterol binding;cholesterol transporter activity;triglyceride binding;phosphatidylcholine binding